Howard Burris Selected Research

XL147

11/2015	Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
3/2015	Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
1/2015	Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Howard Burris Research Topics

Disease

30	Neoplasms (Cancer) 05/2022 - 04/2005
13	Breast Neoplasms (Breast Cancer) 05/2022 - 05/2004
5	Exanthema (Rash) 10/2020 - 02/2007
5	Disease Progression 12/2011 - 05/2004
4	Neutropenia 01/2023 - 05/2003
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 05/2003
3	Biliary Tract Neoplasms (Biliary Tract Cancer) 11/2023 - 01/2021
3	Diarrhea 11/2021 - 01/2015
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 06/2005
3	Pancreatic Neoplasms (Pancreatic Cancer) 12/2011 - 03/2008
2	Carcinoma (Carcinomatosis) 01/2022 - 12/2020
2	Ovarian Neoplasms (Ovarian Cancer) 12/2021 - 01/2018
2	Fatigue 04/2021 - 03/2015
2	Peripheral Nervous System Diseases (PNS Diseases) 04/2021 - 01/2015
2	Hyperphosphatemia 12/2020 - 01/2017
2	Adenocarcinoma 12/2011 - 04/2008
1	Alopecia (Baldness) 04/2021
1	Nausea 04/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2020
1	Glioma (Gliomas) 10/2020
1	Myocardial Infarction 10/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Chondrosarcoma 01/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2019
1	Sarcoma (Soft Tissue Sarcoma) 01/2018
1	Dyspnea (Shortness of Breath) 04/2017
1	Arthralgia (Joint Pain) 04/2017
1	Hypertension (High Blood Pressure) 04/2017
1	Myalgia 04/2017

Drug/Important Bio-Agent (IBA)

9	Trastuzumab (Herceptin)FDA Link 01/2021 - 05/2004
6	ErbB Receptors (EGF Receptor)IBA 05/2022 - 01/2016
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 03/2008
4	Gemcitabine FDA Link 08/2022 - 03/2008
4	Tyrosine Kinase InhibitorsIBA 01/2022 - 03/2008
4	pertuzumabIBA 01/2021 - 01/2017
3	Hormones (Hormone)IBA 05/2022 - 11/2015
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2022 - 01/2017
3	infigratinibIBA 01/2022 - 01/2017
3	PlatinumIBA 12/2021 - 01/2018
3	taxaneIBA 04/2021 - 05/2003
3	Everolimus FDA Link 10/2018 - 04/2008
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 03/2008
3	human ERBB2 proteinIBA 01/2018 - 09/2014
3	Phosphotransferases (Kinase)IBA 01/2017 - 04/2005
3	XL147IBA 11/2015 - 01/2015
2	durvalumabIBA 11/2023 - 08/2022
2	Cisplatin (Platino)FDA LinkGeneric 08/2022 - 01/2011
2	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2019
2	Cetuximab (Erbitux)FDA Link 01/2021 - 02/2007
2	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 12/2020 - 01/2017
2	ivosidenibIBA 10/2020 - 01/2020
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 10/2020 - 01/2020
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 10/2020 - 01/2015
2	ravoxertinibIBA 10/2020 - 01/2020
2	Aromatase InhibitorsIBA 10/2018 - 11/2015
2	Capecitabine (Xeloda)FDA Link 10/2018 - 06/2005
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 03/2008
2	Letrozole (Femara)FDA LinkGeneric 04/2017 - 11/2015
2	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2015 - 01/2015
2	TOR Serine-Threonine KinasesIBA 11/2015 - 04/2008
2	TabletsIBA 03/2015 - 01/2015
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 05/2004
2	Docetaxel (Taxotere)FDA Link 12/2013 - 05/2003
2	MLN8054IBA 04/2011 - 02/2011
2	Aurora Kinase AIBA 04/2011 - 02/2011
2	Panitumumab (Vectibix)FDA Link 01/2011 - 01/2009
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	Lipase (Acid Lipase)FDA Link 11/2021
1	Glycoproteins (Glycoprotein)IBA 11/2021
1	Fatty Acid Synthases (Fatty Acid Synthase)IBA 04/2021
1	TVB-2640IBA 04/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2021
1	cobimetinibIBA 10/2020
1	Mitogen-Activated Protein KinasesIBA 10/2020
1	EnzymesIBA 01/2020
1	alpha-hydroxyglutarateIBA 01/2020
1	Granzymes (Granzyme)IBA 01/2019
1	atezolizumabIBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2019
1	navoximodIBA 01/2019
1	Estrogen ReceptorsIBA 10/2018
1	exemestane (Aromasin)FDA Link 10/2018
1	HhAntag691IBA 01/2018
1	dactolisibIBA 01/2018
1	niraparibIBA 01/2018
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2018
1	VemurafenibIBA 01/2018
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2018
1	Anastrozole (Arimidex)FDA LinkGeneric 04/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	Ado-Trastuzumab EmtansineIBA 01/2017
1	Checkpoint Kinase 1IBA 01/2016
1	prexasertibIBA 01/2016
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2015

Therapy/Procedure

22	Therapeutics 05/2022 - 04/2003
7	Drug Therapy (Chemotherapy) 11/2023 - 04/2008
1	Immunotherapy 11/2023
1	Salvage Therapy 01/2022